SS
VTGN icon

Steve Schonfeld’s VistaGen Therapeutics VTGN Stock Holding History

Steve Schonfeld’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,589
Closed -$15.2K – 3043
2026
Q1 		$15.2K Buy
26,589
+4,853
+22% +$2.95K ﹤0.01% 2070
2025
Q4 		$14.4K Buy
21,736
+10,853
+100% +$39.2K ﹤0.01% 1945
2025
Q3 		$38.6K Buy
+10,883
New +$32.5K ﹤0.01% 2077
2023
Q4 		– Sell
-138,500
Closed -$726K – 2258
2023
Q3 		$726K Buy
+138,500
New +$615K 0.01% 1113
2022
Q3 		– Sell
-5,837
Closed -$155K – 3185
2022
Q2 		$155K Buy
5,837
+7
+0.1% +$247 ﹤0.01% 1991
2022
Q1 		$217K Sell
5,830
-7,043
-55% -$307K ﹤0.01% 1901
2021
Q4 		$753K Sell
12,873
-1,210
-9% -$78.7K 0.01% 1068
2021
Q3 		$1.16M Sell
14,083
-6,370
-31% -$554K 0.01% 905
2021
Q2 		$1.93M Buy
20,453
+11,460
+127% +$849K 0.02% 720
2021
Q1 		$574K Buy
8,993
+6,390
+245% +$427K 0.01% 1095
2020
Q4 		$152K Buy
+2,603
New +$66.4K ﹤0.01% 1393

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Steve Schonfeld's VTGN Position: Q2 2026 in Review

Steve Schonfeld sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 26,589 shares — an estimated $15.2K sold.

Steve Schonfeld first reported a position in VTGN in Q4 2020 and held it in 11 quarters. The position peaked at $1.93M in Q2 2021. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Steve Schonfeld reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 26,589 VistaGen Therapeutics shares in Q2 2026, an estimated $15.2K.
  • Steve Schonfeld first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 11 quarters.
  • Steve Schonfeld's VistaGen Therapeutics position peaked at $1.93M in Q2 2021.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.